From: Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands
Group no. | Treatment | Incidence (%) | Multiplicity (no. of lesions / mouse, means ± SD) | ||||||
---|---|---|---|---|---|---|---|---|---|
 |  | Mucosal ulcer | Total dysplasia | Dysplasia with: | Mucosal ulcer | Total dysplasia | Dysplasia with: | ||
 |  |  |  | Mild atypia | Severe atypia |  |  | Mild atypia | Severe atypia |
1 | AOM/DSS | 40% | 90% | 80% | 50% | 0.5 ± 0.7 | 3.2 ± 1.5 | 1.4 ± 1.0 | 1.1 ± 1.3 |
2 | AOM/DSS/0.04% Nimesulide | 10% | 90% | 80% | 50% | 0.1 ± 0.3 | 2.2 ± 2.3 | 1.2 ± 0.9 | 0.6 ± 0.7 |
3 | AOM/DSS/0.05% Troglitazone | 20% | 90% | 50% | 30% | 0.3 ± 0.7 | 2.1 ± 2.2 | 0.7 ± 0.8 | 0.8 ± 1.6 |
4 | AOM/DSS/0.05% Bezafibrate | 30% | 80% | 60% | 20% | 0.4 ± 0.7 | 1.9 ± 1.8 | 0.9 ± 1.0 | 0.4 ± 0.8 |